此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Priming the Epileptic Brain: tVNS to Improve Efficacy of add-on AED in Patients With Focal Epilepsy (PREP)

2021年12月17日 更新者:Eindhoven University of Technology

Priming the Epileptic Brain - Determining the Effect of Temporarily Addition of Transcutaneous Vagal Nerve Stimulation When Starting an add-on AED (in This Case Brivaracetam) in Patients With Refractory Focal Epilepsy

The most prevalent neurological disorder with also immense burden of disease, epilepsy, is in over 30 percent of patients difficult to treat. The ideal treatment regime would give complete control of disease in an early stage, not only for patient well-being, but also to prevent the onset of persistent pathologic epileptic networks in the brain. The first step in treatment is the trial, and error, of multiple anti-epileptic drugs (AEDs), while invasive brain stimulation (BS) techniques with network modulating properties are saved as a last resort. The investigators hypothesize that pharmacotherapeutic treatment of epilepsy can be more successful after "priming" (preparing) the brain using BS as a short-term neuromodulation treatment. The limitation of testing this hypothesis is the invasive aspect of the most used classic vagal nerve stimulation (VNS) treatment for epilepsy, but the recent development of transcutaneous vagal nerve stimulation (tVNS) offered a possibility to combine chemical and electrical modulation in an earlier stage of disease, which is not tested before. The investigators want to determine the priming effect on the epileptic brain of tVNS, to make it more susceptible to add-on treatment with Brivaracetam (BRV), an AED. In addition, the investigators aim to visualize these changes in the brain because of priming, possibly altered network-organisation.

研究概览

地位

招聘中

干预/治疗

详细说明

Background of the study: The most prevalent neurological disorder with also immense burden of disease, epilepsy, is in over 30 percent of patients difficult to treat. The ideal treatment regime would give complete control of disease in an early stage, not only for patient well-being, but also to prevent the onset of persistent pathologic epileptic networks in the brain. The first step in treatment is the trial, and error, of multiple anti-epileptic drugs (AEDs), while invasive brain stimulation (BS) techniques with network modulating properties are saved as a last resort. The investigators hypothesize that pharmacotherapeutic treatment of epilepsy can be more successful after "priming" (preparing) the brain using BS as a short-term neuromodulation treatment. The limitation of testing this hypothesis is the invasive aspect of the most used classic vagal nerve stimulation (VNS) treatment for epilepsy, but the recent development of transcutaneous vagal nerve stimulation (tVNS) offered a possibility to combine chemical and electrical modulation in an earlier stage of disease, which is not tested before.

Objective of the study: Determine the priming effect on the epileptic brain of tVNS, to make it more susceptible to add-on treatment with Brivaracetam (BRV), an AED. In addition, the investigators aim to visualize these changes in the brain because of priming, possibly altered network-organisation.

Study design: Randomized Controlled Trial. Study population: Adults with a refractory (continuing of seizures despite 2 tried AEDs) focal epilepsy and therefore have an indication for start of Brivaracetam. Intervention (if applicable): One group receives transcutaneous vagal nerve stimulation (tVNS) 4 hours daily for the first 3 months of brivaracetam treatment. Primary study parameters/outcome of the study: Scoring on a composite index combining seizure reduction, improvement of cognition and quality of life. Secondary study parameters/outcome of the study (if applicable): Seizure reduction, seizure freedom rates, seizure severity, cognition, mood state, adverse events tVNS and brivaracetam, change in brain network properties.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable): Besides minor temporary side effects no risk is attributed to tVNS. Because of the study one extra visit is necessary, besides regular clinical follow-up. The 3 visits do require some more time than usual because of the questionnaires, MRI and short cognitive tests. The burden of the telephone calls is very limited, since it only consists of a few short questions. Patients with claustrophobia are excluded, but the requirement of lying still can be somewhat uncomfortable. The eye tracking device uses a camera in the video screen, with no burden at all.

研究类型

介入性

注册 (预期的)

66

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Angelique A Stuurman, Msc
  • 电话号码:0031402279777
  • 邮箱:prep@tue.nl

研究联系人备份

  • 姓名:Rob R Mestrom, Dr
  • 电话号码:0031402279777
  • 邮箱:prep@tue.nl

学习地点

    • Noord Brabant
      • Heeze、Noord Brabant、荷兰、5590 AB
        • 招聘中
        • Stichting Kempenhaeghe
        • 接触:
          • Angelique Stuurman
          • 电话号码:0031 0402279777
          • 邮箱:prep@tue.nl

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Focal epilepsy which is refractory (at least 2 different AEDs tried) and therefore has an indication for start of brivaracetam
  • Age ≥ 18 years.
  • IQ > 70 defined as any form of secondary education

Exclusion Criteria:

  • - Inclusion not possible within 2 weeks after start of brivaracetam
  • History of a progressive cerebral disorder (neurodegenerative diseases, tumours)
  • History of psychogenic nonepileptic seizures (PNES)
  • Inability to provide informed consent
  • Any contra-indication for brivaracetam
  • Current or recent use (exposed ≤ 90 days)
  • Current or recent use (exposed ≤ 90 days) of levetiracetam
  • Current treatment with neurostimulation
  • Inability of handling the tVNS device personally
  • Subjects that have a current diagnosis of cardiac arrhythmic disease
  • Any contraindication for tVNS: pregnancy, active implants (such as cardiac pacemakers of cochlear implants) or cerebral shunts (e.g. ventriculo-peritoneal shunts with valve)
  • Any contraindication for MRI: metallic foreign body, pacemaker, claustrophobia, pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Brivaracetam + Transcutaneous vagal nerve stimulation
Start of Brivaracetam (treatment as usual), combined with tVNS in the first 3 months of treatment
Cerbomed NEMOS
无干预:Brivaracetam
Start of Brivaracetam (treatment as usual)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Epilepsy frequency
大体时间:6 months
Seizure reduction (in % at 3 and 6 months in respect to baseline)
6 months
Epilepsy frequency
大体时间:6 months
Seizure freedom rates (defined as the percentage of subjects with 100% reduction from baseline seizure frequency)
6 months
Seizure severity
大体时间:6 months
Assessed by the National Hospital Seizure Severity Scale - NHS3, comparing scores at 3 and 6 months to baseline). Score range 1-27 (higher score = more severe).
6 months

次要结果测量

结果测量
措施说明
大体时间
Brain networks
大体时间:3 months
Detect changes in network properties by comparing fMRI (functional MRI) data at 3 months with baseline (independent component analysis)
3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Marian M Majoie, Prof. Dr.、ACE Kempenhaeghe

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年8月1日

初级完成 (预期的)

2023年7月1日

研究完成 (预期的)

2023年7月1日

研究注册日期

首次提交

2021年7月2日

首先提交符合 QC 标准的

2021年12月17日

首次发布 (实际的)

2022年1月6日

研究记录更新

最后更新发布 (实际的)

2022年1月6日

上次提交的符合 QC 标准的更新

2021年12月17日

最后验证

2021年12月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • PREP_001

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅